Neurotech Reports Forecasts $15.1 Billion Market by 2024
A newly published market research report from Neurotech Reports, the publisher of this newsletter, estimates that the worldwide market for neurotechnology products to be $9.1 billion in 2020, growing to $15.1 billion in 2024. This represents a CAGR of 13 percent. The report, titled The Market for Neurotechnology: 2020-2024, was authored Cavuoto, Jennifer French, Jeremy Koff, and Margot Puerta. It i…
Enduring Our Pain
It’s far too early to assess what effect the current coronavirus situation will have on the neurotechnology industry. But the timing is far from optimal. Just at the point when venture capital investment in neurotech startups had reached record levels, the current standstill in economic activity has created a time of uncertainty for entrepreneurs. The virus’ impact on VC investment will certainly be one of the topics to come up during our third annual Bioelectronic Medicine Forum on April 7.
Neuromodulation Professionals Join Pain Physicians at AAPM Annual Meeting
The 36th annual American Academy of Pain Medicine convened in National Harbor, MD in late February. The event is a culmination of the multiple disciplines in clinical practice, the latest research in a patient-centered approach, and emerging methods to treat people living with chronic pain. The overwhelming sentiment at the meeting was that treatments are not singular in nature but complementary an…
Neuromodulation Professionals Join Pain Physicians at AAPM Annual Meeting
The 36th annual American Academy of Pain Medicine convened in National Harbor, MD in late February. The event is a culmination of the multiple disciplines in clinical practice, the latest research in a patient-centered approach, and emerging methods to treat people living with chronic pain. The overwhelming sentiment at the meeting was that treatments are not singular in nature but complementary an…
TMS Vendors Seek Out New Indications and Markets
The market for transcranial magnetic stimulation systems, which is currently driven largely -resistant depression, is likely to expand in the years ahead as manufacturers and investigators devise new therapeutic applications. TMS is currently approved major depression and obsessive compulsive disorder. Earlier this month, BrainsWay Ltd. announced results from a randomized controlled double-blind clinical trial assessing the safety and efficacy of the company’s deep TMS system for the treatment of adults with ADHD.
Emerging Firms to Present at Bioelectronic Medicine Forum in NYC
Executives of several emerging bioelectronic medicine firms will present at the Third Annual Bioelectronic Medicine Forum, to take place on April 7, 2020 in New York City. The conference, produced , will also feature sessions related to investment, regulatory and reimbursement, and translational issues. Among the promising entrepreneurs tentatively scheduled to present are Ash Attia, CEO of Bionic…
Who Was First?
As is the case with most areas of science and engineering, the field of neurotechnology has moved forward as the result of pioneering discoveries that have led to new products, new therapeutic approaches, and new branches of investigation. As is also often the case, there can be disagreement among researchers as to who was the first to make that important discovery. Such was the case in the field of optics regarding who invented the laser.
Neuromodulation Entrepreneurs Join Strategics at 23rd Annual NANS Meeting
The 23rd Annual meeting of the North American Neuromodulation Society took place in Las Vegas, NV, earlier this month—the last meeting at this venue before it moves to Orlando, FL next year. As one of the largest conferences on the topic of neuromodulation, this event brings together discoveries in basic and clinical neuroscience with innovations in neural engineering. This year the program featured a half-day session called Emerging Technology Forum.
Glial Cell Findings May Alter SCS Market Landscape
New findings on the role of glial cells in modulating pain may have a fundamental impact on the market for spinal cord stimulation systems. The topic was one of the major themes at the recent NANS conference in Las Vegas and at least one vendor has invested heavily in the new approach. In a keynote address at the meeting, Linda Watkins from the University of Colorado described the role that non-neuronal cells such as glia play in the pain pathway.
Investors Join Entrepreneurs and Strategics at Bioelectronic Medicine Forum in NYC
About 85 executives and entrepreneurs took part in the second annual Bioelectronic Medicine Forum held in New York City earlier this month. The agenda featured four discussion panels covering topics like investments, digital health, regulatory and reimbursement, and future technology. More than a dozen entrepreneurs presented their ventures and technology innovations at the event and NBR editor Jam…